Every material Form 8-K Opus Genetics, Inc. has filed with the SEC since September 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Opus Genetics said Chief Scientific and Development Officer Ashwath Jayagopal will step out of that role effective October 19, 2026, and move into a six-month consulting arrangement to provide transition services at the company's request. The change is an executive departure at a senior scientific and development post, and the filing gives no successor name.
Ashwath Jayagopal's role as Chief Scientific and Development Officer ends with a separation date of October 19, 2026.
He will provide transition services under a six-month consulting arrangement, paid at $250 per hour.
His outstanding vested options as of the separation date stay exercisable during the consulting term.
The full letter agreement will be filed as an exhibit to the Form 10-K for the fiscal year ended December 31, 2026.
Opus Genetics presented interim clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy trials at Retina in Rio 2026 on October 14, 2026, and furnished the press release and slides in this 8-K. The company said the data are interim and based on small participant groups, and it expects Phase 3 dosing for OPGx-LCA5 to begin in the fourth quarter of 2026.
OPGx-BEST1 low-dose Cohort 1: three of four evaluable participants (75%) showed improved retinal sensitivity in the treated transitional zone.
OPGx-LCA5 adults showed sustained improvements in visual acuity and light sensitivity through 24 months; three pediatric participants showed results through six months.
OPGx-BEST1 high-dose Cohort 2 has completed enrollment with 11 participants.
Phase 3 dosing for OPGx-LCA5 is expected in the fourth quarter of 2026.
Opus Genetics filed a revised data presentation on September 11, 2026, correcting an error in the Cohort 1 results of its OPGx-BEST1 gene therapy trial that it presented at its September 9, 2026 investor conference. The error was in converting logMAR visual acuity to ETDRS letters on Slide 15, and the company calls it immaterial. The filing also lists each participant's three-month letter change, and two participants show losses in the treated eye, so shareholders may want to review the corrected figures.
Slide 15, which charts mean best-corrected visual acuity from baseline through 3 months in Cohort 1, was corrected for a logMAR-to-ETDRS translation error.
Corrected three-month changes in the treated eye: 101-101 up 12 letters, 101-104 up 1, 102-101 down 10, 102-102 up 2, 101-106 up 6.
Corrected three-month changes in the fellow eye: 101-101 up 4 letters, 101-104 down 7, 102-101 down 8, 102-102 down 5, 101-106 up 2.
Microperimetry grid images for baseline and 3 months were added to the appendix; the original presentation was furnished on September 9, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Opus Genetics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →